CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC) Files An 8-K Other Events
Item 8.01 Other Events.
Declaration of Quarterly Cash Dividend on 6% Convertible
Exchangeable Preferred Stock
On December 7, 2016, the Board of Directors (the
Board) of Cyclacel Pharmaceuticals, Inc. (the
Company) declared a quarterly cash dividend in
the amount of $0.15 per share on the Companys 6% Convertible
Exchangeable Preferred Stock (Preferred Stock).
The cash dividend will be payable on February 1, 2017 to the
holders of record of the Preferred Stock as of the close of
business on January 18, 2017.
The Board considered numerous factors in determining whether to
declare the quarterly dividend, including the requisite financial
analysis and determination of a surplus. While the Board will
analyze the advisability of the declaration of dividends in
future quarters, there is no assurance that future quarterly
dividends will be declared.
About CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC)
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors. CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC) Recent Trading Information
CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC) closed its last trading session down -0.18 at 3.82 with 58,260 shares trading hands.